1.64
price up icon0.00%   0.00
after-market Dopo l'orario di chiusura: 1.73 0.09 +5.49%
loading
Precedente Chiudi:
$1.64
Aprire:
$1.51
Volume 24 ore:
27,423
Relative Volume:
0.40
Capitalizzazione di mercato:
$77.26M
Reddito:
$18.11M
Utile/perdita netta:
$-18.95M
Rapporto P/E:
-3.7486
EPS:
-0.4375
Flusso di cassa netto:
-
1 W Prestazione:
-1.50%
1M Prestazione:
-20.00%
6M Prestazione:
-27.75%
1 anno Prestazione:
-43.45%
Intervallo 1D:
Value
$1.50
$1.7566
Intervallo di 1 settimana:
Value
$1.325
$1.87
Portata 52W:
Value
$1.325
$3.5807

Adagene Inc Adr Stock (ADAG) Company Profile

Name
Nome
Adagene Inc Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
138
Name
Cinguettio
Name
Prossima data di guadagno
2024-03-28
Name
Ultimi documenti SEC
Name
ADAG's Discussions on Twitter

Confronta ADAG con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ADAG
Adagene Inc Adr
1.64 77.26M 18.11M -18.95M 0 -0.4375
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-31 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-06-25 Iniziato China Renaissance Buy
2021-03-08 Iniziato Goldman Buy
2021-03-08 Iniziato Jefferies Buy
2021-03-08 Iniziato Morgan Stanley Overweight

Adagene Inc Adr Borsa (ADAG) Ultime notizie

pulisher
Mar 27, 2025

Adagene stock hits 52-week low at $1.62 amid market challenges By Investing.com - Investing.com South Africa

Mar 27, 2025
pulisher
Mar 27, 2025

Adagene stock hits 52-week low at $1.62 amid market challenges - Investing.com

Mar 27, 2025
pulisher
Mar 25, 2025

Adagene (ADAG) to Release Quarterly Earnings on Thursday - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

Adagene Reports 33% Overall Response Rate in Phase 2 Expansion of Muzastotug for MSS CRC, Highlights Financial Position and Future Milestones - Nasdaq

Mar 24, 2025
pulisher
Mar 24, 2025

Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

Adagene Reveals Breakthrough Cancer Trial Results in 2024 Financial Update - Stock Titan

Mar 24, 2025
pulisher
Mar 14, 2025

Adagene Inc. (NASDAQ:ADAG) Short Interest Down 55.9% in February - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit - GlobeNewswire

Mar 13, 2025
pulisher
Mar 13, 2025

Adagene Inc. to Present ADG126 SAFEbody® Data at 11th Annual Immuno-Oncology 360⁰ Summit in Boston - Nasdaq

Mar 13, 2025
pulisher
Mar 13, 2025

Adagene's Revolutionary Cancer Treatment Targets CTLA-4: Key Presentation Coming to IO360 Summit - StockTitan

Mar 13, 2025
pulisher
Mar 12, 2025

Adagene to Present at the Leerink Partners Global Biopharma Conference 2024, Business Wires News - AsiaOne

Mar 12, 2025
pulisher
Mar 07, 2025

Adagene Announces Participation At Leerink’s Global Healthcare Conference 2025 - BERNAMA

Mar 07, 2025
pulisher
Mar 07, 2025

Adagene to Present at Leerink’s Global Healthcare Conference 2025 - GlobeNewswire

Mar 07, 2025
pulisher
Mar 06, 2025

Adagene to Present at Leerink's Global Healthcare Conference 2025 - The Manila Times

Mar 06, 2025
pulisher
Mar 06, 2025

Can Adagene's CEO Reveal New Strategic Plans at Upcoming Leerink Conference? - StockTitan

Mar 06, 2025
pulisher
Feb 27, 2025

Adagene Inc. to Initiate Phase 2 Trial of ADG126 for Colorectal Cancer with Enrollment Starting in April 2025 - Nasdaq

Feb 27, 2025
pulisher
Feb 27, 2025

Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Could This New Colorectal Cancer Trial Change Pre-Surgery Treatment? Adagene Tests ADG126 - StockTitan

Feb 27, 2025
pulisher
Feb 23, 2025

Head to Head Analysis: Rafael (NYSE:RFL) versus Adagene (NASDAQ:ADAG) - Defense World

Feb 23, 2025
pulisher
Feb 16, 2025

Short Interest in Adagene Inc. (NASDAQ:ADAG) Declines By 50.2% - MarketBeat

Feb 16, 2025
pulisher
Feb 13, 2025

Adagene Inc. (NASDAQ:ADAG) Short Interest Update - Defense World

Feb 13, 2025
pulisher
Feb 13, 2025

Head to Head Survey: Adagene (NASDAQ:ADAG) and Corvus Pharmaceuticals (NASDAQ:CRVS) - Defense World

Feb 13, 2025
pulisher
Feb 04, 2025

Morgan Stanley Downgrades Adagene (NASDAQ:ADAG) to Equal Weight - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Adagene Inc. (NASDAQ:ADAG) Sees Large Increase in Short Interest - MarketBeat

Feb 04, 2025
pulisher
Feb 03, 2025

Adagene (NASDAQ:ADAG) Cut to “Equal Weight” at Morgan Stanley - Defense World

Feb 03, 2025
pulisher
Feb 01, 2025

FY2024 Earnings Estimate for Adagene Issued By HC Wainwright - MarketBeat

Feb 01, 2025
pulisher
Jan 31, 2025

HC Wainwright Estimates Adagene FY2029 Earnings - MarketBeat

Jan 31, 2025
pulisher
Jan 31, 2025

Morgan Stanley Downgrades Adagene to Equal Weight From Overweight -January 31, 2025 at 07:57 am EST - Marketscreener.com

Jan 31, 2025
pulisher
Jan 31, 2025

Adagene Inc. (NASDAQ:ADAG) Sees Significant Growth in Short Interest - Defense World

Jan 31, 2025
pulisher
Jan 30, 2025

Adagene Reports Promising Results in Colorectal Cancer Study - TipRanks

Jan 30, 2025
pulisher
Jan 29, 2025

FY2029 Earnings Forecast for Adagene Issued By HC Wainwright - Defense World

Jan 29, 2025
pulisher
Jan 28, 2025

Adagene Announces Updated Data from Phase 1b/2 Study of - GlobeNewswire

Jan 28, 2025
pulisher
Jan 27, 2025

Adagene (NASDAQ:ADAG) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat

Jan 27, 2025
pulisher
Jan 27, 2025

H.C. Wainwright lifts Adagene stock target to $8 on ASCO data - Investing.com

Jan 27, 2025
pulisher
Jan 27, 2025

Adagene reports positive colorectal cancer trial results - Investing.com India

Jan 27, 2025
pulisher
Jan 27, 2025

ADAGAdagene Inc. American Depositary Shares Latest Stock News & Market Updates - StockTitan

Jan 27, 2025
pulisher
Jan 27, 2025

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium - The Manila Times

Jan 27, 2025
pulisher
Jan 27, 2025

Adagene's Muzastotug Shows 33% Response Rate in Colorectal Cancer Trial - StockTitan

Jan 27, 2025
pulisher
Jan 22, 2025

Adagene to present new ADG126 clinical data at ASCO-GI - MSN

Jan 22, 2025
pulisher
Jan 22, 2025

Adagene to present new ADG126 clinical data at ASCO-GI By Investing.com - Investing.com Australia

Jan 22, 2025
pulisher
Jan 22, 2025

Adagene to Announce Updated Data from Phase 1b/2 Study of - GlobeNewswire

Jan 22, 2025

Adagene Inc Adr Azioni (ADAG) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Capitalizzazione:     |  Volume (24 ore):